OptiNose Management

Management criteria checks 0/4

OptiNose's CEO is Ramy Mahmoud, appointed in Jan 2023, has a tenure of 1.25 years. total yearly compensation is $2.41M, comprised of 26.8% salary and 73.2% bonuses, including company stock and options. directly owns 0.35% of the company’s shares, worth €321.82K. The average tenure of the management team and the board of directors is 1.8 years and 2.8 years respectively.

Key information

Ramy Mahmoud

Chief executive officer

US$2.4m

Total compensation

CEO salary percentage	26.8%
CEO tenure	1.3yrs
CEO ownership	0.4%
Management average tenure	1.8yrs
Board average tenure	2.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ramy Mahmoud's remuneration changed compared to OptiNose's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$2m	US$647k	-US$35m
Sep 30 2023	n/a	n/a	-US$41m
Jun 30 2023	n/a	n/a	-US$46m
Mar 31 2023	n/a	n/a	-US$68m
Dec 31 2022	US$1m	US$504k	-US$75m
Sep 30 2022	n/a	n/a	-US$75m
Jun 30 2022	n/a	n/a	-US$77m
Mar 31 2022	n/a	n/a	-US$82m
Dec 31 2021	US$1m	US$504k	-US$82m
Sep 30 2021	n/a	n/a	-US$91m
Jun 30 2021	n/a	n/a	-US$95m
Mar 31 2021	n/a	n/a	-US$97m
Dec 31 2020	US$2m	US$489k	-US$100m
Sep 30 2020	n/a	n/a	-US$101m
Jun 30 2020	n/a	n/a	-US$109m
Mar 31 2020	n/a	n/a	-US$110m
Dec 31 2019	US$1m	US$475k	-US$110m
Sep 30 2019	n/a	n/a	-US$111m
Jun 30 2019	n/a	n/a	-US$108m
Mar 31 2019	n/a	n/a	-US$105m
Dec 31 2018	US$609k	US$451k	-US$107m
Sep 30 2018	n/a	n/a	-US$101m
Jun 30 2018	n/a	n/a	-US$93m
Mar 31 2018	n/a	n/a	-US$81m
Dec 31 2017	US$3m	US$438k	-US$62m

Compensation vs Market: Ramy's total compensation ($USD2.41M) is above average for companies of similar size in the German market ($USD401.52K).

Compensation vs Earnings: Ramy's compensation has increased whilst the company is unprofitable.

CEO

Ramy Mahmoud (58 yo)

1.3yrs

Tenure

US$2,414,265

Compensation

Dr. Ramy A. Mahmoud, M.D., M.P.H., serves as Chief Executive Officer and Director of OptiNose US Inc. since January 2023. He serves as Chief Executive Officer & Director of OptiNose, Inc. since January 31,...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Ramy Mahmoud	CEO & Director	1.3yrs	US$2.41m	0.35% $ 321.8k
Michael Marino	Chief Legal Officer & Corporate Secretary	7.3yrs	US$1.32m	0.15% $ 132.2k
Anthony Krick	VP of Finance & Chief Accounting Officer	1.8yrs	no data	0.0054% $ 4.9k
Jonathan Neely	Vice President of Investor Relations & Business Development	no data	no data	no data
Karen Brophy	Chief Human Resources Officer & VP of Human Resources	6.2yrs	no data	no data
Paul Spence	Chief Commercial Officer	1.3yrs	US$664.02k	no data

1.8yrs

Average Tenure

54yo

Average Age

Experienced Management: 0OP's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Ramy Mahmoud	CEO & Director	1.3yrs	US$2.41m	0.35% $ 321.8k
Sandra Helton	Independent Director	6.2yrs	US$103.42k	0% $ 0
R. Fletcher	Independent Chairman	2yrs	US$120.22k	0% $ 0
Eric Bednarski	Independent Director	2.3yrs	US$88.42k	0% $ 0
Wilhelmus C. Groenhuysen	Independent Director	6.5yrs	US$100.92k	0% $ 0
Tomas Heyman	Independent Director	3.3yrs	US$96.88k	0% $ 0
Kyle Dempsey	Independent Director	2.3yrs	US$90.92k	0% $ 0
Catherine Owen	Independent Director	3.8yrs	US$89.95k	0% $ 0

2.8yrs

Average Tenure

65yo

Average Age

Experienced Board: 0OP's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

OptiNose Management

Management criteria checks 0/4

Key information

Recent management updates

OptiNose, Inc., Annual General Meeting, Jun 06, 2024

CEO & Director recently sold €64k worth of stock

OptiNose, Inc. Approves Board Changes

Optinose Announces Board Changes

Optinose Announces Departure of Michele Janis as Acting Chief Financial Officer

High number of new directors

Recent updates

OptiNose, Inc., Annual General Meeting, Jun 06, 2024

OptiNose, Inc. Provides Earnings Guidance for the Full Year 2025

Full year 2023 earnings released: US$0.32 loss per share (vs US$0.87 loss in FY 2022)

OptiNose, Inc. Provides Earnings Guidance for the First Quarter of 2024

New minor risk - Profitability

OptiNose, Inc. to Report Q4, 2023 Results on Mar 07, 2024

New minor risk - Insider selling

CEO & Director recently sold €64k worth of stock

Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology

Forecast to breakeven in 2026

Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE

OptiNose, Inc. Revises Revenue Guidance for the Full Year of 2023

Forecast to breakeven in 2025

OptiNose, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Second quarter 2023 earnings released: EPS: US$0.023 (vs US$0.23 loss in 2Q 2022)

OptiNose, Inc. to Report Q2, 2023 Results on Aug 10, 2023

New minor risk - Profitability

No longer forecast to breakeven

OptiNose, Inc. Approves Board Changes

First quarter 2023 earnings released: US$0.17 loss per share (vs US$0.31 loss in 1Q 2022)

Optinose, Inc. Provides Revenue Guidance for Full Year of 2023

Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE

Full year 2022 earnings released: US$0.87 loss per share (vs US$1.45 loss in FY 2021)

Optinose Announces Board Changes

Optinose Announces Departure of Michele Janis as Acting Chief Financial Officer

No longer forecast to breakeven

OptiNose, Inc. has completed a Follow-on Equity Offering in the amount of $50.008 million.

Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.32 loss in 3Q 2021)

High number of new directors

Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.32 loss in 3Q 2021)

OptiNose, Inc. Provides Revenue Guidance for the Full Year 2022

OptiNose, Inc. Announces ReOpen2 Presentation at the American College of Asthma, Allergy, and Immunology (ACAAI) 2022 Annual Scientific Meeting

OptiNose, Inc. to Report Q3, 2022 Results on Nov 10, 2022

CEO & Director recently sold €190k worth of stock

High number of new directors

OptiNose, Inc. Provides Revenue Guidance for the Full Year of 2022

OptiNose, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Optinose Announces XHANCE Significantly Reduced Incidence of Exacerbations for Patients with Chronic Sinusitis in Landmark ReOpen Program

Optinose Announces Additional Positive Results from ReOpen2 and Initial Results from Pooled Analyses of Both Trials in the ReOpen Program

Optinose Announces Positive Top-Line Results of Reopen2, Its Second Phase 3 Clinical Trial of Xhance for Treatment of Chronic Sinusitis

OptiNose, Inc. Announces Executive Appointments

Optinose, Inc. Updates Revenue Guidance for 2022

OptiNose, Inc. to Report Q1, 2022 Results on May 12, 2022

OptiNose, Inc., Annual General Meeting, Jun 08, 2022

Optinose Announces Appointment of R. John Fletcher to its Board of Directors as a Class III Director

OptiNose, Inc. Provides Revenue Guidance for the First Quarter and Full Year of 2022

OptiNose, Inc. to Report Q4, 2021 Results on Mar 08, 2022

OptiNose, Inc.(NasdaqGS:OPTN) dropped from Russell 3000E Index

Optinose Provides Update on Chronic Sinusitis Clinical Trials

Optinose, Inc. Expects Top-Line Results from One of Its Clinical Trials Evaluating XHANCE as A Potential Treatment for Chronic Sinusitis by the End of 2021

OptiNose, Inc. Enters into Amendment No. 1 to that Certain Manufacture and Supply Agreement with Contract Pharmaceuticals Limited

OptiNose, Inc. to Report Q4, 2020 Results on Mar 03, 2021

Optinose Announces Board Changes

Optinose, Inc. Announces Management Changes

OptiNose Notifies Nasdaq That It Intends to Appoint A Third Member to the Company’s Audit Committee

OptiNose, Inc. has completed a Follow-on Equity Offering in the amount of $35.1 million.

First half earnings released

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age